TriangleHEALTH PROFESSIONAL · SOURCE READING
Biological therapy
Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Several biological agents have been evaluated for the treatment of endometrial cancer.
Mammalian target of rapamycin (mTOR) inhibitors.Endometrial cancers often show alterations in the AKT-PI3K pathway, making mTOR inhibitors an attractive choice for clinical study in patients with metastatic or recurrent disease. Phase II studies of single-agent everolimus [24] and ridaforolimus [25,26] have predominantly shown disease stabilization. A phase II study of the combination of everolimus and letrozole showed a 32% response rate.[27][Level of evidence C3]
Source links and citations
Bevacizumab.
Bevacizumab.
Bevacizumab was used as a single agent in a phase II trial. The overall response rate was 13.5%.[28][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice